Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Pediatr Hematol Oncol ; 37(5): 431-437, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32166993

RESUMO

D-2-hydroxyglutaric aciduria (D-2-HGA) is a rare metabolic disorder characterized by developmental delay, hypotonia, and bi-allelic mutations in D-2-hydroxyglutarate dehydrogenase (D2HGDH) or a single gain-of-function mutation in isocitrate dehydrogenase 2 (IDH2). Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria (MC-HGA) is a type of D-2-HGA that has been previously reported in ten patients (OMIM 614875), three of whom had somatic mosaicism for R132 variants in isocitrate dehydrogenase 1 (IDH1). We describe a 3-year-old boy with MC-HGA who subsequently developed acute myeloid leukemia (AML) and was found to have an IDH1 R132C mutation in a leukemic bone marrow sample. Further testing revealed presence of somatic mosaicism for IDH1 R132C variant, suggesting an association of IDH1 in inducing myeloid leukemogenesis.


Assuntos
Encefalopatias Metabólicas Congênitas/genética , Condromatose/genética , Isocitrato Desidrogenase/genética , Leucemia Mieloide Aguda/genética , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Encefalopatias Metabólicas Congênitas/complicações , Pré-Escolar , Condromatose/complicações , Condromatose/tratamento farmacológico , Transplante de Células-Tronco Hematopoéticas , Humanos , Leucemia Mieloide Aguda/complicações , Leucemia Mieloide Aguda/tratamento farmacológico , Masculino , Mutação , Resultado do Tratamento
2.
Nature ; 499(7459): 491-5, 2013 Jul 25.
Artigo em Inglês | MEDLINE | ID: mdl-23863940

RESUMO

The tyrosine phosphatase SHP2, encoded by PTPN11, is required for the survival, proliferation and differentiation of various cell types. Germline activating mutations in PTPN11 cause Noonan syndrome, whereas somatic PTPN11 mutations cause childhood myeloproliferative disease and contribute to some solid tumours. Recently, heterozygous inactivating mutations in PTPN11 were found in metachondromatosis, a rare inherited disorder featuring multiple exostoses, enchondromas, joint destruction and bony deformities. The detailed pathogenesis of this disorder has remained unclear. Here we use a conditional knockout (floxed) Ptpn11 allele (Ptpn11(fl)) and Cre recombinase transgenic mice to delete Ptpn11 specifically in monocytes, macrophages and osteoclasts (lysozyme M-Cre; LysMCre) or in cathepsin K (Ctsk)-expressing cells, previously thought to be osteoclasts. LysMCre;Ptpn11(fl/fl) mice had mild osteopetrosis. Notably, however, CtskCre;Ptpn11(fl/fl) mice developed features very similar to metachondromatosis. Lineage tracing revealed a novel population of CtskCre-expressing cells in the perichondrial groove of Ranvier that display markers and functional properties consistent with mesenchymal progenitors. Chondroid neoplasms arise from these cells and show decreased extracellular signal-regulated kinase (ERK) pathway activation, increased Indian hedgehog (Ihh) and parathyroid hormone-related protein (Pthrp, also known as Pthlh) expression and excessive proliferation. Shp2-deficient chondroprogenitors had decreased fibroblast growth factor-evoked ERK activation and enhanced Ihh and Pthrp expression, whereas fibroblast growth factor receptor (FGFR) or mitogen-activated protein kinase kinase (MEK) inhibitor treatment of chondroid cells increased Ihh and Pthrp expression. Importantly, smoothened inhibitor treatment ameliorated metachondromatosis features in CtskCre;Ptpn11(fl/fl) mice. Thus, in contrast to its pro-oncogenic role in haematopoietic and epithelial cells, Ptpn11 is a tumour suppressor in cartilage, acting through a FGFR/MEK/ERK-dependent pathway in a novel progenitor cell population to prevent excessive Ihh production.


Assuntos
Neoplasias Ósseas/metabolismo , Neoplasias Ósseas/patologia , Condromatose/metabolismo , Condromatose/patologia , Exostose Múltipla Hereditária/metabolismo , Exostose Múltipla Hereditária/patologia , Proteínas Hedgehog/metabolismo , Células-Tronco Mesenquimais/metabolismo , Proteína Tirosina Fosfatase não Receptora Tipo 11/deficiência , Transdução de Sinais , Animais , Neoplasias Ósseas/tratamento farmacológico , Neoplasias Ósseas/genética , Cartilagem/metabolismo , Cartilagem/patologia , Catepsina K/deficiência , Catepsina K/genética , Catepsina K/metabolismo , Divisão Celular , Linhagem da Célula , Condromatose/tratamento farmacológico , Condromatose/genética , Exostose Múltipla Hereditária/tratamento farmacológico , Exostose Múltipla Hereditária/genética , Fatores de Crescimento de Fibroblastos/metabolismo , Deleção de Genes , Regulação da Expressão Gênica/efeitos dos fármacos , Genes Supressores de Tumor/fisiologia , Proteínas Hedgehog/antagonistas & inibidores , Sistema de Sinalização das MAP Quinases , Macrófagos/metabolismo , Células-Tronco Mesenquimais/citologia , Camundongos , Camundongos Knockout , Camundongos Transgênicos , Quinases de Proteína Quinase Ativadas por Mitógeno/antagonistas & inibidores , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , Monócitos/metabolismo , Osteoclastos/metabolismo , Osteopetrose/genética , Osteopetrose/metabolismo , Osteopetrose/patologia , Proteína Relacionada ao Hormônio Paratireóideo/metabolismo , Proteína Tirosina Fosfatase não Receptora Tipo 11/genética , Proteína Tirosina Fosfatase não Receptora Tipo 11/metabolismo , Transdução de Sinais/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA